The MeCo Score is a prognostic and predictive biomarker that stratifies early-stage breast cancer patients for risk of metastasis caused by mechanical conditioning, and it provides the rationale for targeted prevention in high-risk patients using low-toxicity antifibrotic drugs as "mechanical deconditioning therapy."